Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 19, 2018 | June 22, 2018 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | November 01, 2023 | November 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 19, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.75 · Expires 2028-06-19 | Direct | 22,000 |
Reported balance
After 2018-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-19 · Grant · Acquired 22,000 · Balance 22,000 |
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Matinas BioPharma Holdings, Inc.
Report date November 01, 2023 · Filed November 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2033-11-01 | Direct | 437,244 |
Reported balance
After 2023-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-01 · Grant · Acquired 437,244 · Balance 437,244 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2018 Filed Jun 15, 2018 11:30 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008559 · edgar.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 21:09 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 31,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000359 · conradmatinas_fm4mar302018.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,911,179 F1 · shares: On March 30, 2018, the Reporting Person was issued 31,579 shares of common stock par value $.0001 per share which vest immediately upon grant. Read SEC document |
| September 07, 2017 Filed Sep 7, 2017 21:06 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock | 100,000 | $1.30 | $130,000.00 |
DisclosureSEC source: 0000905718-17-000825 · conrad_fm4sept72017.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,879,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.40, inclusive. The reporting person undertakes to provide Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:59 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantDirector Stock Option Grant (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001140361-17-025881 · doc1.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Shares · 22,000 shares Expires 2027-06-21 Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009166 · edgar.xml · derivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009166 · edgar.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| July 29, 2016 Filed Oct 2, 2019 22:13 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries A Preferred Stock · Derivative | 20,000 | $5.00 Strike: $0.00 | $100,000.00 |
DisclosureSEC source: 0001493152-19-014915 · ownership.xml · derivative · entry 7 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F4 · derivative.expiration_date: Converts automatically into Common Stock upon the earlier of (i) notice by the Issuer to the holders that the Issuer elected to convert all outstanding shares of Class A Preferred, (ii) July 29, 2019, (iii) the approval of the Issuer's MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of the Issuer's MAT2501 product candidate. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.